The Global. The arrival in Europe of the first biosimilar in April 2006 marked a turning point in the companies' pricing policy. A decade later, the effects of the twenty of these drugs present in the continental market are evident according to the data analyzed by the consultancy IMS Health. In fact, a report in this regard ensures that the market price of epoetins has been reduced by 26 percent, that of granulocyte colony-stimulating factor by 23 percent, that of human growth hormones by 13 percent, and 4 percent that of necrotic antitumor factor.

READ MORE